BR112014025830A2 - - Google Patents

Info

Publication number
BR112014025830A2
BR112014025830A2 BR112014025830A BR112014025830A BR112014025830A2 BR 112014025830 A2 BR112014025830 A2 BR 112014025830A2 BR 112014025830 A BR112014025830 A BR 112014025830A BR 112014025830 A BR112014025830 A BR 112014025830A BR 112014025830 A2 BR112014025830 A2 BR 112014025830A2
Authority
BR
Brazil
Application number
BR112014025830A
Other languages
Portuguese (pt)
Other versions
BR112014025830A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112014025830A2 publication Critical patent/BR112014025830A2/pt
Publication of BR112014025830A8 publication Critical patent/BR112014025830A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112014025830A 2012-04-20 2013-04-18 Polipeptídeos de ligação ao cd3 BR112014025830A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261636557P 2012-04-20 2012-04-20
US201261718635P 2012-10-25 2012-10-25
US201361799849P 2013-03-15 2013-03-15
PCT/US2013/037135 WO2013158856A2 (en) 2012-04-20 2013-04-18 Cd3 binding polypeptides

Publications (2)

Publication Number Publication Date
BR112014025830A2 true BR112014025830A2 (ru) 2017-06-20
BR112014025830A8 BR112014025830A8 (pt) 2017-10-10

Family

ID=49384230

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025830A BR112014025830A8 (pt) 2012-04-20 2013-04-18 Polipeptídeos de ligação ao cd3

Country Status (16)

Country Link
US (1) US10202452B2 (ru)
EP (1) EP2839019A4 (ru)
JP (2) JP6509724B2 (ru)
KR (1) KR20150004856A (ru)
CN (1) CN104487587A (ru)
AU (2) AU2013249267A1 (ru)
BR (1) BR112014025830A8 (ru)
CA (1) CA2870545A1 (ru)
HK (2) HK1207398A1 (ru)
IL (1) IL235093B (ru)
IN (1) IN2014MN02293A (ru)
MX (1) MX366813B (ru)
RU (1) RU2673153C2 (ru)
SG (2) SG10201608307WA (ru)
UA (1) UA119227C2 (ru)
WO (1) WO2013158856A2 (ru)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP4303236A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
JP2014518615A (ja) 2011-04-22 2014-08-07 エマージェント プロダクト デベロップメント シアトル， エルエルシー 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
AU2013249267A1 (en) 2012-04-20 2014-10-23 Aptevo Research And Development Llc CD3 binding polypeptides
EP3050896B1 (en) 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
CA2937866A1 (en) 2014-01-24 2015-07-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Antibodies against f glycoprotein of hendra and nipah viruses
AU2015283704A1 (en) 2014-07-01 2016-12-15 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
CN107108738A (zh) 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
PT3247725T (pt) 2015-01-23 2020-10-07 Sanofi Sa Anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam de forma biespecífica a cd3 e/ou a cd123
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
SG10201912666PA (en) 2015-04-13 2020-02-27 Pfizer Chimeric antigen receptors targeting b-cell maturation antigen
PE20221262A1 (es) 2015-04-13 2022-08-16 Pfizer Anticuerpos terapeuticos y sus usos
WO2016178996A1 (en) * 2015-05-01 2016-11-10 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
CN104892765B (zh) * 2015-06-29 2018-04-10 深圳市国创纳米抗体技术有限公司 一种抗CD3抗原和Her‑2抗原的双特异性抗体
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
EP3352760A4 (en) * 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3 BINDING POLYPEPTIDES
CN108026179A (zh) * 2015-10-02 2018-05-11 豪夫迈·罗氏有限公司 结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
AU2016368469B2 (en) 2015-12-09 2023-11-02 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
MX2018010988A (es) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
CN107365387B (zh) * 2016-05-12 2022-03-15 阿思科力(苏州)生物科技有限公司 一种双特异性抗原结合构建体及其制备方法和应用
US11339225B2 (en) 2016-05-12 2022-05-24 Asclepius (Suzhou) Technology Company Group, Co., Ltd. Bispecific antigen-binding construct and preparation method and use thereof
SG11201810327XA (en) 2016-05-20 2018-12-28 Harpoon Therapeutics Inc Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
BR112018073761A2 (pt) * 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteínas de ligação ao cd3 de fragmento variável de cadeia única
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN110603266A (zh) 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
CN106117358A (zh) * 2016-06-16 2016-11-16 中山大学 抗cd3单域抗体
CN106084047A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106117361A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106084049A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106146661A (zh) * 2016-06-17 2016-11-23 中山大学 抗cd3单域抗体
CN106117359A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106084048A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106117360A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106084046A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
CN106146662A (zh) * 2016-07-18 2016-11-23 中山大学 抗cd3单域抗体
CR20220408A (es) * 2016-09-14 2022-10-20 Teneobio Inc ANTICUERPOS DE UNIÓN A CD3(Divisional del Expediente 2019-198)
CN109952112B (zh) * 2016-09-21 2024-09-06 阿帕特夫研究和发展有限公司 Cd123结合蛋白和相关的组合物和方法
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
CA3044659A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN110325209A (zh) 2017-02-24 2019-10-11 宏观基因有限公司 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
IL312322A (en) 2017-06-20 2024-06-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
CN111201242A (zh) * 2017-06-22 2020-05-26 财团法人生物技术开发中心 不对称异二聚fc-scfv融合抗globo h及抗cd3双特异性抗体及其在癌症治疗上的用途
EP3676294A4 (en) * 2017-08-28 2021-12-22 Systimmune, Inc. ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF
JP7066837B2 (ja) 2017-10-13 2022-05-13 ハープーン セラピューティクス，インク． Ｂ細胞成熟抗原結合タンパク質
PT3694529T (pt) 2017-10-13 2024-09-20 Harpoon Therapeutics Inc Proteínas triespecíficas e métodos de utilização
TW202428622A (zh) 2017-10-18 2024-07-16 瑞士商諾華公司 用於選擇性蛋白質降解的組合物及方法
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
WO2019108900A1 (en) 2017-11-30 2019-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
JOP20200157A1 (ar) 2017-12-22 2022-10-30 Teneobio Inc أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22
US20200368268A1 (en) 2018-01-08 2020-11-26 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US11685781B2 (en) 2018-02-15 2023-06-27 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
CN112533950B (zh) * 2018-06-29 2023-03-10 多玛医药科技(苏州)有限公司 抗CD3e抗体及其用途
MA53094A (fr) 2018-07-02 2021-05-12 Amgen Inc Protéine de liaison à l'antigène anti-steap1
BR112021003305A2 (pt) 2018-08-31 2021-05-25 Novartis Ag métodos para produzir células que expressam receptor de antígeno quimérico
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CA3110706A1 (en) * 2018-09-19 2020-03-26 FUJIFILM Cellular Dynamics, Inc. Protein l for activation and expansion of chimeric antigen receptor-modified immune cells
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CN116396386A (zh) * 2018-12-07 2023-07-07 江苏恒瑞医药股份有限公司 Cd3抗体及其药物用途
CN116178547A (zh) * 2019-02-22 2023-05-30 武汉友芝友生物制药股份有限公司 Cd3抗原结合片段及其应用
TW202045207A (zh) 2019-02-25 2020-12-16 瑞士商諾華公司 用於病毒遞送之介孔二氧化矽顆粒組成物
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
CA3140816A1 (en) 2019-06-14 2020-12-17 Nathan Trinklein Multispecific heavy chain antibodies binding to cd22 and cd3
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
CN113005088B (zh) * 2019-12-19 2024-06-04 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
MX2022008655A (es) 2020-01-13 2022-09-23 Aptevo Res & Development Llc Metodos y composiciones para prevenir la adsorcion de proteinas terapeuticas en componentes del sistema de administracion de farmacos.
IL294458A (en) 2020-01-13 2022-09-01 Aptevo Res & Development Llc Formulations for protein treatments
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
IL295604A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
IL298046A (en) 2020-05-11 2023-01-01 Janssen Biotech Inc Treatment methods for multiple myeloma
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
EP4199960A2 (en) 2020-08-21 2023-06-28 Novartis AG Compositions and methods for in vivo generation of car expressing cells
IL301956A (en) * 2020-10-07 2023-06-01 Dren Bio Inc Antibodies against dectin-1 and methods of using them
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
CN118056008A (zh) 2021-04-27 2024-05-17 诺华股份有限公司 病毒载体生产系统
US20240209116A1 (en) * 2021-04-28 2024-06-27 Ngm Biopharmaceuticals, Inc. Multimerization of binding molecules having an antibody constant region variant
JP2024509664A (ja) 2021-04-30 2024-03-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による治療のための投薬
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
WO2022240865A1 (en) * 2021-05-11 2022-11-17 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
JP2024519964A (ja) 2021-05-21 2024-05-21 アプティーボ リサーチ アンド デベロップメント エルエルシー タンパク質治療薬のための投薬レジメン
JP2024531364A (ja) 2021-08-20 2024-08-29 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
WO2023081705A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
WO2023180353A1 (en) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
TW202404637A (zh) 2022-04-13 2024-02-01 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
CN115029318B (zh) * 2022-05-12 2022-12-20 成都赋智健康科技有限公司 携带多特异性抗体基因的间充质干细胞及其制药用途
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
PT737207E (pt) 1994-01-11 2005-02-28 Dyax Corp Inibidores de plasmina humana derivados de dominios kunitz
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE69731836T2 (de) 1996-07-23 2005-12-01 Pangenetics B.V. Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
DE69922159T2 (de) 1998-01-23 2005-12-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Mehrzweck-antikörperderivate
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU2002226930A1 (en) * 2000-11-17 2002-05-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2433877C (en) 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20040044182A1 (en) 2001-09-17 2004-03-04 Hunt Joan S Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g
EP3502133A1 (en) 2002-09-27 2019-06-26 Xencor, Inc. Optimized fc variants and methods for their generation
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
CA2555503C (en) 2004-02-16 2018-03-27 Micromet Ag Humanized anti-cd3 bispecific binding molecules having reduced immunogenicity, uses and compositions relating thereto
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
EP3770174A1 (en) 2005-10-11 2021-01-27 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
WO2007114319A1 (ja) * 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
WO2007145941A2 (en) 2006-06-06 2007-12-21 Tolerrx, Inc. Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
WO2008051448A2 (en) 2006-10-19 2008-05-02 Tolerx, Inc. Methods and compositions for efficient removal of protein a from binding molecule preparations
US20100015142A1 (en) 2006-12-21 2010-01-21 Macrogenics Inc. Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity
AU2008287195A1 (en) 2007-07-06 2009-02-19 Emergent Product Development Seattle, Llc Binding peptides having a C-terminally disposed specific binding domain
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
CN102203258A (zh) 2008-07-02 2011-09-28 新兴产品开发西雅图有限公司 TGF-β拮抗剂多靶点结合蛋白
CA2729749A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tnf-a antagonist multi-target binding proteins
KR20110043643A (ko) 2008-07-02 2011-04-27 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 인터루킨 6 면역치료제
CA2732574A1 (en) 2008-07-28 2010-02-04 Philip Tan Multi-specific binding proteins targeting b cell disorders
CN102164960A (zh) 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
EP2344540B1 (en) 2008-10-02 2017-11-29 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US20110217302A1 (en) * 2008-10-10 2011-09-08 Emergent Product Development Seattle, Llc TCR Complex Immunotherapeutics
CA2761233A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
ME02505B (me) * 2009-12-29 2017-02-20 Aptevo Res & Development Llc Heterodimerni vezujući proteini i njihove upotrebe
JP2014518615A (ja) 2011-04-22 2014-08-07 エマージェント プロダクト デベロップメント シアトル， エルエルシー 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
KR101308922B1 (ko) * 2012-02-15 2013-09-23 주식회사 경동나비엔 연소기기용 듀얼 벤츄리
AU2013249267A1 (en) 2012-04-20 2014-10-23 Aptevo Research And Development Llc CD3 binding polypeptides

Also Published As

Publication number Publication date
RU2014142166A (ru) 2016-06-10
AU2017228643A1 (en) 2017-10-05
JP2018138039A (ja) 2018-09-06
EP2839019A4 (en) 2016-03-30
BR112014025830A8 (pt) 2017-10-10
KR20150004856A (ko) 2015-01-13
WO2013158856A2 (en) 2013-10-24
HK1207398A1 (en) 2016-01-29
HK1208707A1 (en) 2016-03-11
CA2870545A1 (en) 2013-10-24
IL235093A0 (en) 2014-12-31
IN2014MN02293A (ru) 2015-08-07
US20150232557A1 (en) 2015-08-20
MX2014012578A (es) 2015-05-11
IL235093B (en) 2019-09-26
EP2839019A2 (en) 2015-02-25
SG10201608307WA (en) 2016-11-29
CN104487587A (zh) 2015-04-01
UA119227C2 (uk) 2019-05-27
RU2673153C2 (ru) 2018-11-22
AU2017228643B2 (en) 2019-12-05
SG11201406346SA (en) 2014-11-27
AU2013249267A1 (en) 2014-10-23
JP2015521032A (ja) 2015-07-27
JP6509724B2 (ja) 2019-05-08
MX366813B (es) 2019-07-25
US10202452B2 (en) 2019-02-12

Similar Documents

Publication Publication Date Title
BR112014025830A2 (ru)
BR112014017635A2 (ru)
BR112014018331A2 (ru)
BR112014017614A2 (ru)
BR112014017625A2 (ru)
BR112014019838A2 (ru)
AR092201A1 (ru)
BR112014017638A2 (ru)
BR112014018155A2 (ru)
BR112014024753A2 (ru)
BR112014019146A2 (ru)
BR112013027865A2 (ru)
BR112014017634A2 (ru)
BR112014017609A2 (ru)
BR112014017644A2 (ru)
BR112014017858A2 (ru)
BR112014017618A2 (ru)
BR112014013184A8 (ru)
BR112014017630A2 (ru)
BR112014017621A2 (ru)
BR112014017622A2 (ru)
BR112014017627A2 (ru)
BR112014017623A2 (ru)
BR112014017631A2 (ru)
BR112014017641A2 (ru)

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: APTEVO RESEARCH AND DEVELOPMENT LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: COM BASE NA RESOLUCAO 81/2013, SOLICITA-SE QUE SEJA APRESENTADO, EM ATE 60 (SESSENTA) DIAS, DECLARACAO DE LISTAGEM DE SEQUENCIA ASSINADA, NOS MOLDES DA RESOLUCAO NO 187 DE 27/04/2017, REFERENTE AO CONTEUDO APRESENTADO NA PETICAO NO 020140034220 DE 17/11/2014.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements